No change
Add to watchlist
Create an alert
Stocks and Shares ISAKuros Biosciences AG is a Switzerland-based biotechnology company engaged in the discovery, development and commercialization of biopharmaceutical products known as Immunodrugs. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The Company has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The Company has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.
Company Information
About this company
Key people
Chris Fair
Chief Executive Officer, Executive Director, Member of the Executive Board
Daniel Geiger
Chief Financial Officer, Member of the Executive Board
Sjoerd Musters
Chief Operating Officer, Member of the Executive Board
Joost de Bruijn
Executive Director, Member of the Executive Board, President of Innovation and Strategy
John Griffin
Chief Commercial Officer, Member of the Executive Board
Philippe Saudan
Chief Development Officer, Member of the Executive Board
Clemens Van Blitterswijk
Non-Executive Chairman of the Board of Directors
Kimberley A. Elting
Non-Executive Member of the Board of Directors
Oliver Walker
Non-Executive Member of the Board of Directors
Click to see more
Key facts
- Shares in issue39.18m
- EPICKURN
- ISINCH0325814116
- LocationSwitzerland
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market capCHF 989.15m
- Employees122
- ExchangeSIX Swiss Exchange
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.